Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Frederick Hudson sold 5,369 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the company, valued at $3,057,501.93. This represents a 8.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Supernus Pharmaceuticals Price Performance

SUPN opened at $50.82 on Wednesday. The business’s 50-day moving average price is $51.26 and its two-hundred day moving average price is $49.17. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $59.68. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -74.73, a P/E/G ratio of 1.56 and a beta of 0.70.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State Street Corp increased its position in shares of Supernus Pharmaceuticals by 1.4% during the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after purchasing an additional 31,668 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after buying an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after buying an additional 162,905 shares in the last quarter. Stephens Investment Management Group LLC grew its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Finally, Stifel Nicolaus lifted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.